Gene:
KCNH2
potassium voltage-gated channel, subfamily H (eag-related), member 2

PharmGKB contains no dosing guidelines for this gene. To report known dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB contains no drug labels with pharmacogenomic information for this gene. To report a drug label with PGx, click here.

PharmGKB contains no Clinical Variants that meet the highest level of criteria.

To see more Clinical Variants with lower levels of criteria, click the button at the bottom of the table.

Position ? Drug ? Relevance ? Strength of
Evidence ?
rs12720441

To see relevance please register or sign in.

3

Download a summary of all Clinical Annotations available.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

PharmGKB contains no genetic tests for this gene. To report genetic tests, click here.

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page.

Links in the "Drugs" column lead to PharmGKB Drug Pages.

Variant?
(build 132)
Alternate Names ? Drugs ? Alleles ?
(+ chr strand)
Function ? Amino Acid?
Translation
rs12720441 R784W, c.1330C>T, c.2350C>T, g.11242927G>A, g.150278237G>A, g.32711C>T, p.Arg444Trp, p.Arg784Trp
G > A
Missense
Arg444Trp
rs1805123 K897T, KCNH2:K897T, c.1670A>C, c.2690A>C, g.11241157T>G, g.34481A>C, p.Lys557Thr, p.Lys897Thr
T > G
T > A
T > C
Missense
Lys897Thr
rs36210421 KCNH2: R1047L, R1047L, c.2120G>T, c.3140G>T, g.11240051C>A, g.35587G>T, p.Arg1047Leu, p.Arg707Leu
C > A
Missense
Arg707Leu
rs3807375 KCNH2:rs3807375, c.307+4589G>A, g.11262833C>T, g.12805G>A
C > T
Not Available
rs3815459 KCNH2:rs3815459, c.2132+22G>A, c.3152+22G>A, g.11240017C>T, g.35621G>A
C > G
C > T
C > A
Not Available
Alleles, Functions, and Amino Acid Translations are all sourced from dbSNP build 132

Overview

Alternate Names:  ERG-1; H-ERG; cause of Long QT Syndrome Type 2; eag homolog; eag-related; eag-related protein 1; ether-a-go-go-related gene potassium channel 1; ether-a-go-go-related potassium channel protein; ether-a-go-go-related protein 1; hERG-1; human eag-related gene; potassium channel HERG; potassium voltage-gated channel subfamily H member 2; potassium voltage-gated channel, subfamily H, member 2; voltage-gated potassium channel; voltage-gated potassium channel subunit Kv11.1; voltage-gated potassium channel, subfamily H, member 2
Alternate Symbols:  ERG1; HERG; HERG1; Kv11.1; LQT2; SQT1; erg1
PharmGKB Accession Id: PA212

Details

Cytogenetic Location: chr7 : q36.1 - q36.1
GP mRNA Boundary: chr7 : 150642049 - 150675014
GP Gene Boundary: chr7 : 150639049 - 150685014
Strand: minus
Product Name: No data available
The mRNA boundaries are calculated using the gene's default feature set from NCBI, mapped onto the UCSC Golden Path. PharmGKB sets gene boundaries by expanding the mRNA boundaries by no less than 10,000 bases upstream (5') and 3,000 bases downstream (3') to allow for potential regulatory regions.

PharmGKB Curated Pathways

Pathways created internally by PharmGKB based primarily on literature evidence.

  1. Antiarrhythmic Pathway, Pharmacodynamics
    Pharmacodynamic pathway of antiarrhythmic drugs in a stylized cardiac myocyte.

External Pathways

Links to non-PharmGKB pathways.

PharmGKB contains no links to external pathways for this gene. To report a pathway, click here.

No related genes are available

Curated Information ?

Evidence Drug Class
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
antiarrhythmics, class i and iii

Curated Information ?

Publications related to KCNH2: 55

No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics of drugs withdrawn from the market. Pharmacogenomics. 2012. Zhang Wei, et al. [Article:22256871@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Drug- and non-drug-associated QT interval prolongation. British journal of clinical pharmacology. 2010. van Noord Charlotte, et al. [Article:20642543@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Effects of the selective alpha 1a-adrenoceptor antagonist silodosin on ECGs of healthy men in a randomized, double-blind, placebo- and moxifloxacin-controlled study. Clinical pharmacology and therapeutics. 2010. Morganroth J, et al. [Article:20220748@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
KCNH2 pharmacogenomics summary. Pharmacogenetics and genomics. 2010. Oshiro Connie, et al. [Article:20150828@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Drug-induced long QT syndrome. Pharmacological reviews. 2010. Kannankeril Prince, et al. [Article:21079043@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Arrhythmia pharmacogenomics: methodological considerations. Current pharmaceutical design. 2009. Roden Dan M, et al. [Article:19925424@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Common candidate gene variants are associated with QT interval duration in the general population. Journal of internal medicine. 2009. Marjamaa A, et al. [Article:19019189@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Common variants at ten loci influence QT interval duration in the QTGEN Study. Nature genetics. 2009. Newton-Cheh Christopher, et al. [Article:19305408@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Protective effect of KCNH2 single nucleotide polymorphism K897T in LQTS families and identification of novel KCNQ1 and KCNH2 mutations. BMC medical genetics. 2008. Zhang Xianqin, et al. [Article:18808722@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
hERG potassium channels and the structural basis of drug-induced arrhythmias. Chemical research in toxicology. 2008. Mitcheson John S. [Article:18447395@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Strategy for a genetic assessment of antipsychotic and antidepressant-related proarrhythmia. Current medicinal chemistry. 2008. Drago Antonio, et al. [Article:18855674@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
The non-synonymous coding IKr-channel variant KCNH2-K897T is associated with atrial fibrillation: results from a systematic candidate gene-based analysis of KCNH2 (HERG). European heart journal. 2008. Sinner Moritz F, et al. [Article:18222980@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Hydroxyzine, a first generation H(1)-receptor antagonist, inhibits human ether-a-go-go-related gene (HERG) current and causes syncope in a patient with the HERG mutation. Journal of pharmacological sciences. 2008. Sakaguchi Tomoko, et al. [Article:19057127@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Molecular determinants of hERG channel block by terfenadine and cisapride. Journal of pharmacological sciences. 2008. Kamiya Kaichiro, et al. [Article:18987434@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Drug binding to the inactivated state is necessary but not sufficient for high-affinity binding to human ether-à-go-go-related gene channels. Molecular pharmacology. 2008. Perrin Mark J, et al. [Article:18701618@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The human ERG1 channel polymorphism, K897T, creates a phosphorylation site that inhibits channel activity. Proceedings of the National Academy of Sciences of the United States of America. 2008. Gentile Saverio, et al. [Article:18791070@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Inhibition of the HERG potassium channel by the tricyclic antidepressant doxepin. Biochemical pharmacology. 2007. Duncan R S, et al. [Article:17560554@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Common genetic variation in KCNH2 is associated with QT interval duration: the Framingham Heart Study. Circulation. 2007. Newton-Cheh Christopher, et al. [Article:17709632@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Stereoselective block of hERG channel by (S)-methadone and QT interval prolongation in CYP2B6 slow metabolizers. Clinical pharmacology and therapeutics. 2007. Eap C B, et al. [Article:17329992@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Drug-induced long QT and torsade de pointes: recent advances. Current opinion in cardiology. 2007. Kannankeril Prince J, et al. [Article:17143043@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Confirmation of associations between ion channel gene SNPs and QTc interval duration in healthy subjects. European journal of human genetics : EJHG. 2007. Gouas L, et al. [Article:17534376@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genetic variants in the epithelial sodium channel associate with oedema in type 2 diabetic patients receiving the peroxisome proliferator-activated receptor gamma agonist farglitazar. Pharmacogenetics and genomics. 2007. Spraggs Colin, et al. [Article:18004211@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
HERG is protected from pharmacological block by alpha-1,2-glucosyltransferase function. The Journal of biological chemistry. 2007. Nakajima Tadashi, et al. [Article:17189275@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
hERG potassium channels and cardiac arrhythmia. Nature. 2006. Sanguinetti Michael C, et al. [Article:16554806@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Comparative evaluation of HERG currents and QT intervals following challenge with suspected torsadogenic and nontorsadogenic drugs. The Journal of pharmacology and experimental therapeutics. 2006. Katchman Alexander N, et al. [Article:16278312@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Differentiation of arrhythmia risk of the antibacterials moxifloxacin, erythromycin, and telithromycin based on analysis of monophasic action potential duration alternans and cardiac instability. The Journal of pharmacology and experimental therapeutics. 2006. Wisialowski Todd, et al. [Article:16614168@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pentamidine reduces hERG expression to prolong the QT interval. British journal of pharmacology. 2005. Cordes Jason S, et al. [Article:15711592@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Common variants in myocardial ion channel genes modify the QT interval in the general population: results from the KORA study. Circulation research. 2005. Pfeufer Arne, et al. [Article:15746444@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The phenothiazine drugs inhibit hERG potassium channels. Drug and chemical toxicology. 2005. Kim Ki-Suk, et al. [Article:16051556@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Predictive in silico modeling for hERG channel blockers. Drug discovery today. 2005. Aronov Alex M. [Article:15718164@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Drug-induced torsades de pointes: the evolving role of pharmacogenetics. Heart rhythm : the official journal of the Heart Rhythm Society. 2005. Fitzgerald Patrick T, et al. [Article:16253929@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genetic susceptibility to acquired long QT syndrome: pharmacologic challenge in first-degree relatives. Heart rhythm : the official journal of the Heart Rhythm Society. 2005. Kannankeril Prince J, et al. [Article:15851285@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Molecular and functional characterization of common polymorphisms in HERG (KCNH2) potassium channels. American journal of physiology. Heart and circulatory physiology. 2004. Anson Blake D, et al. [Article:14975928@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Probucol aggravates long QT syndrome associated with a novel missense mutation M124T in the N-terminus of HERG. Clinical science (London, England : 1979). 2004. Hayashi Kenshi, et al. [Article:15043509@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Drug-induced torsades de pointes and implications for drug development. Journal of cardiovascular electrophysiology. 2004. Fenichel Robert R, et al. [Article:15090000@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Role of a KCNH2 polymorphism (R1047 L) in dofetilide-induced Torsades de Pointes. Journal of molecular and cellular cardiology. 2004. Sun Zhuoqian, et al. [Article:15522280@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Mechanisms of arsenic-induced prolongation of cardiac repolarization. Molecular pharmacology. 2004. Ficker Eckhard, et al. [Article:15213294@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Inhibition of cardiac HERG potassium channels by the atypical antidepressant trazodone. Naunyn-Schmiedeberg's archives of pharmacology. 2004. Zitron Edgar, et al. [Article:15322737@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Drug-induced prolongation of the QT interval. The New England journal of medicine. 2004. Roden Dan M. [Article:14999113@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
QT prolongation and fatal arrhythmias: a review of clinical implications and effects of drugs. American journal of therapeutics. 2003. Cubeddu Luigi X. [Article:14624285@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Characterisation of recombinant HERG K+ channel blockade by the Class Ia antiarrhythmic drug procainamide. Biochemical and biophysical research communications. 2003. Ridley John M, et al. [Article:12804575@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Understanding the structure-activity relationship of the human ether-a-go-go-related gene cardiac K+ channel. A model for bad behavior. Journal of medicinal chemistry. 2003. Pearlstein Robert, et al. [Article:12747773@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The IKr drug response is modulated by KCR1 in transfected cardiac and noncardiac cell lines. The FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 2003. Kupershmidt Sabina, et al. [Article:14525949@PubMed]
Allelic variants in long-QT disease genes in patients with drug-associated torsades de pointes. Circulation. 2002. Yang Ping, et al. [Article:11997281@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
A comparison of the receptor binding and HERG channel affinities for a series of antipsychotic drugs. European journal of pharmacology. 2002. Kongsamut Sathapana, et al. [Article:12176106@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The antidepressant drug fluoxetine is an inhibitor of human ether-a-go-go-related gene (HERG) potassium channels. The Journal of pharmacology and experimental therapeutics. 2002. Thomas Dierk, et al. [Article:11805215@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
[3H]dofetilide binding to HERG transfected membranes: a potential high throughput preclinical screen. European journal of pharmacology. 2001. Finlayson K, et al. [Article:11698075@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
A structural basis for drug-induced long QT syndrome. Proceedings of the National Academy of Sciences of the United States of America. 2000. Mitcheson J S, et al. [Article:11005845@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
MiRP1 forms IKr potassium channels with HERG and is associated with cardiac arrhythmia. Cell. 1999. Abbott G W, et al. [Article:10219239@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genetic and molecular basis of cardiac arrhythmias: impact on clinical management part III. Circulation. 1999. Priori S G, et al. [Article:9950666@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Block of HERG potassium channels by the antihistamine astemizole and its metabolites desmethylastemizole and norastemizole. Journal of cardiovascular electrophysiology. 1999. Zhou Z, et al. [Article:10376921@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Blockage of the HERG human cardiac K+ channel by the gastrointestinal prokinetic agent cisapride. The American journal of physiology. 1997. Mohammad S, et al. [Article:9374794@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Multiple mechanisms in the long-QT syndrome. Current knowledge, gaps, and future directions. The SADS Foundation Task Force on LQTS. Circulation. 1996. Roden D M, et al. [Article:8873679@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel. Cell. 1995. Sanguinetti M C, et al. [Article:7736582@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Long QT syndrome patients with mutations of the SCN5A and HERG genes have differential responses to Na+ channel blockade and to increases in heart rate. Implications for gene-specific therapy. Circulation. 1995. Schwartz P J, et al. [Article:8521555@PubMed]
PharmGKB® is a registered trademark of HHS and is financially supported by NIH/NIGMS. It is managed at Stanford University (R24 GM61374).
©2001-2012 PharmGKB.